FDA advisors vote in favor of approval for Amgen’s Evenity

An FDA Advisory Committee voted that the overall benefit/risk profile of Amgen’s Evenity was acceptable to support approval, with 15 voting yes for Amgen’s proposed indication, 3 voting yes, but for a different indication, and 1 voting no, according to various press reports of the committee meeting.
https://thefly.com/landingPageNews.php?id=2849869